p53 antibody (C-Term)

Catalog No. ABIN5646912

This Mouse Monoclonal antibody specifically detects p53 in WB, IF, FACS and IHC (fro). It exhibits reactivity toward Human, Mouse, Rat, Monkey, Dog and Hamster.

Quick Overview for p53 antibody (C-Term) (ABIN5646912)

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Reactivity: Human, Mouse, Rat, Monkey, Dog, Hamster

Host: Mouse

Clonality: Monoclonal

Conjugate: This p53 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: PAb 122

Product Details anti-p53 Antibody

Binding Specificity: AA 370-378, C-Term

Characteristics: This antibody is specific to a conserved determinant of the p53 protein. PAb 122 binds to the C-terminus (aa 370-378) of both wild type and mutated p53. When microinjected into nuclei, PAb 122 blocked re-entry into the S-phase of the cell cycle. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. p53 binds to a DNA consensus sequence, the p53 response element, and it regulates normal cell growth cycle events by activating transcription of genes, involved either in progression through the cycle, or causing arrest in G1 when the genome is damaged. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). The protein in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Its the most commonly mutated gene in spontaneously occurring human cancers. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation.

Purification: Purified

Purity: Protein G affinity chromatography

Immunogen: SV40-transformed mouse B4 cells were used as the immunogen for this antibody. Its epitope maps near the C-terminal end (aa 370-378) of p53.

Isotype: IgG2b kappa

Application Details

Application Notes: Variations in protocols, secondaries and substrates may require the p53 antibody to be titered up or down for optimal performance.\. Western blot: 0.5-1 μg/mL,FACS: 0.5-1 μg/million cells,Immunofluorescence: 0.5-1 μg/mL,IHC (Frozen) only: 0.5-1 μg/mL for 30 min at RT

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the p53 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for p53

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Alternative Name: p53 / TP53

Background: This antibody is specific to a conserved determinant of the p53 protein. PAb 122 binds to the C-terminus (aa 370-378) of both wild type and mutated p53. When microinjected into nuclei, PAb 122 blocked re-entry into the S-phase of the cell cycle. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. If it occurs in the germ line, such tumors run in families. p53 binds to a DNA consensus sequence, the p53 response element, and it regulates normal cell growth cycle events by activating transcription of genes, involved either in progression through the cycle, or causing arrest in G1 when the genome is damaged. In most transformed and tumor cells the concentration of p53 is increased 5-1000 fold over the minute concentrations (1000 Molecules cell) in normal cells, principally due to the increased half-life (4 h) compared to that of the wild-type (20 min). The protein in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution. Its the most commonly mutated gene in spontaneously occurring human cancers. Mutations arise with an average frequency of 70 % but incidence varies from zero in carcinoid lung tumors to 97 % in primary melanomas. High concentrations of p53 protein are transiently expressed in human epidermis and superficial dermal fibroblasts following mild ultraviolet irradiation.

Pathways: p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy, Warburg Effect